Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Fate Therapeutics Inc (NASDAQ:FATE)

3.44
Delayed Data
As of Sep 23
 -0.10 / -2.82%
Today’s Change
1.46
Today|||52-Week Range
7.14
+2.08%
Year-to-Date
Can The Uptrend Continue for Fate Therapeutics (FATE)?
Sep 23 / Zacks.com - Paid Partner Content
5 Biotech Stocks That Are Broker Favorites
Sep 13 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close3.54
Today’s open3.58
Day’s range3.30 - 3.63
Volume358,439
Average volume (3 months)306,291
Market cap$99.4M
Dividend yield--
Data as of 3:59pm ET, 09/23/2016

Growth & Valuation

Earnings growth (last year)+7.09%
Earnings growth (this year)+4.38%
Earnings growth (next 5 years)--
Revenue growth (last year)--
P/E ratioNM
Price/Sales35.33
Price/Book2.60

Competitors

 Today’s
change
Today’s
% change
CFRXContraFect Corp+0.14+6.42%
ONSOncobiologics Inc+0.01+0.22%
ADMAADMA Biologics Inc+0.10+1.38%
AKTXAkari Therapeutics P...+0.13+1.47%
Data as of 4:00pm ET, 09/23/2016

Financials

Next reporting dateNovember 8, 2016
EPS forecast (this quarter)-$0.28
Annual revenue (last year)$2.4M
Annual profit (last year)-$30.0M
Net profit margin-1,233.73%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
J. Scott Wolchko
Chief Scientific Officer
Daniel D. Shoemaker
Corporate headquarters
San Diego, California

Forecasts

Search for Jobs